Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Virology, and Nephropathy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MYH9 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MYH9 Recombinant Protein (Motor Domain / Tail Domain) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for ATPase assays and binding screens. |
View MYH9 Products |
| Gene Delivery | MYH9 Promise-ORF / Lentivirus Full-length ORF for stable cell lines, cell migration assays, and localization studies. |
View MYH9 Products |
| Benchmark Ab | Anti-MYH9 Recombinant Antibody Recombinant positive control for western blot, immunofluorescence, and immunoprecipitation. |
View MYH9 Products |
| Validator | MYH9 siRNA Set For knockdown verification in functional assays (migration, invasion, viral entry). |
View MYH9 Products |
| Related Target A | MYH10 Paralog of MYH9 (Non-muscle myosin heavy chain IIB). Essential for selectivity counter-screening to avoid off-target toxicity. |
View MYH10 Products |
| Related Target B | ROCK1 Rho-associated kinase 1. Upstream regulator that phosphorylates myosin light chain, activating MYH9-driven actomyosin contractility. |
View ROCK1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity Counter-Screening (MYH9 vs MYH10/MYH14) | Highly purified MYH9, MYH10, and MYH14 recombinant domains strictly verified by mass spectrometry and SDS-PAGE (>95% purity). |
| Intracellular Target Accessibility & Conformation | High-titer Lentiviral Premade Particles for stable over-expression, enabling native intracellular conformation in live-cell functional assays. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives in Knockdown | Validated siRNA included for specificity checks |
Live MYH9 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of MYH9 (Non-muscle myosin heavy chain IIA / NMHC-IIA) is gaining significant traction across oncology, virology, and nephrology. Traditionally viewed as a structural cytoskeletal protein, recent clinical and mechanistic insights have highlighted MYH9 as a key driver of tumor metastasis, epithelial-mesenchymal transition (EMT), and viral entry (acting as a co-receptor for various viruses). The race for MYH9 therapeutics is intensifying, with major players shifting focus from traditional systemic cytotoxic agents to targeted small-molecule inhibitors, protein degraders (PROTACs), and RNA therapeutics. As first-generation non-muscle myosin inhibitors enter preclinical and early clinical validation, the next wave of R&D is targeting isoform-specific inhibition to bypass cardiotoxicity and systemic neuromuscular side effects.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutions, Biotech Startups | Solid Tumors (Metastasis), FSGS (Nephropathy) | Enzymatic ATPase Assay (Requires high-purity active recombinant MYH9 motor domain) |
| PROTACs / Degraders | Targeted Protein Degradation Pioneers | Refractory/Metastatic Cancers | Ubiquitination & Degradation Kinetics (Requires Lentivirus for stable GFP-MYH9 expression) |
| RNA Therapeutics (siRNA/ASO) | RNAi Therapeutics Developers | Fibrotic Kidney Diseases, Viral Infections | Target Knockdown Validation (Requires validated siRNA controls and quantitative qPCR/WB reagents) |